483
Liuzhou LMZ Co., Ltd.FDA 483 - Liuzhou LMZ Co., Ltd. - July 05, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Liuzhou LMZ Co., Ltd., an OTC drug manufacturer in Liuzhou, Guangxi, China, from July 1-5, 2019, revealed significant deficiencies. The firm failed to establish and follow written procedures for manufacturing and quality control, exhibited inadequate laboratory controls and testing method verification, and maintained deficient records. These issues indicate a lack of adherence to good manufacturing practices.
Open in Dashboard
ID · 18c3ec4b-eb45-480d-b529-85d23b047fbd